Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by wildbird1on Aug 22, 2024 7:48am
238 Views
Post# 36191331

RE:RE:RE:RE:RE:RE:RE:RE:RE:POTENTIAL HOME CANCER TREATMENT

RE:RE:RE:RE:RE:RE:RE:RE:RE:POTENTIAL HOME CANCER TREATMENTExcellent post CancerSlayer...

To complement your post..In the Feb23,2015 PressRelease... 

2015-02-23 | Theralase Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells | TSXV:TLT | Press Release

TLT said'' Rutherrin is able to provide 300% more payload of TLD-1433 to the cancer cell than TLD-1433 alone''

As you said Transferrin is ''a natural transporter of iron in the body'', and Transferrin is a protein produced in the liver and should be 100% safe.

We have 4 compounds..
-TLD-1433 = 100% safe.
-Transferrin=100% safe.
-Rutherrin(TLD-1433 +Transferrin) should also be 100% safe.
-Metformin is also 100% safe (when the dosage is respected).

In short...
The combination of Rutherrin(TLD-1433+Transferrin) and Metformin should also be 100% safe.

A phase 1b safety trial will easily prove the above.


Billion dollard question????
If TLT provide directly to the doctors a kit for treating cancer at home(Bladder, Brain, Lungs...etc)..does it mean that TLT will not need a Big Pharma deal(and TLT will keep 100% of the $profit)...????

The future combination of Metformin&Transferrin looks amazing.

Hold on to your TLT shares.

CancerSlayer wrote:
Rutherrin & TLD 1433 are practically twins from a biological safety profile imo.  Keep in mind, Ruthenium/TLD 1433 closely mimics its relative, iron.  This enables it to have a high "affinity for transferrin" (a natural transporter of iron in the body), which is one of the core reasons for its low in vivo toxicity... as evidenced thus far in our current NMIBC study.  

Based on the composition of Rutherrin (TLD 1433 + transferrin), I see no concerns with safety at the doses likely required.  Futhermore, it's very plausible to conclude that modifying the core of our compound (i.e. changing the ligand) or using a similar metal of the same group (i.e. Osmium, etc.) will "not" significantly change the safety profile, which again is excellent thus far for this family of elements.  JMO.



<< Previous
Bullboard Posts
Next >>